Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Mankind Pharma Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The portfolio is assigned to 2 distinct examiners and 2 distinct art units. BRAUN, MADELINE E is the busiest examiner, with 1 pending matter.
The pending matters are divided between two examination settings. Counsel should expect the need for separate review of claim construction and cited references, while checking that shared formulation, therapeutic, or biological terminology is used consistently across the files.
The available data shows no examiner concentration beyond the identified 1 pending matter. A practical portfolio approach is to coordinate technical evidence and specification support centrally, then adapt the response to the specific rejection and examination style presented in each application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 1 | 68.4% | +25.3% |
| HOLLOMAN, NANNETTE | 1 | 60.7% | +23.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18799812 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GPR119 AGONIST COMPOUNDS AND INTERMEDIATES THEREOF | BRAUN, MADELINE E | — |
| 18730348 | STABLE PHARMACEUTICAL COMPOSITIONS | HOLLOMAN, NANNETTE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18799812 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GPR119 AGONIST COMPOUNDS AND INTERMEDIATES THEREOF | BRAUN, MADELINE E | — |
| 18730348 | STABLE PHARMACEUTICAL COMPOSITIONS | HOLLOMAN, NANNETTE | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18799812 | PROCESSES FOR THE PREPARATION AND PURIFICATION OF GPR119 AGONIST COMPOUNDS AND INTERMEDIATES THEREOF | BRAUN, MADELINE E | 1624 | §102§103§112Other | Non-Final OA | — | Pending | Aug 09, 2024 |
| 18730348 | STABLE PHARMACEUTICAL COMPOSITIONS | HOLLOMAN, NANNETTE | 1612 | §102§103 | Final Rejection | — | Pending | Jul 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMankind Pharma Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Madeline E Braun has the most, with 1 of Mankind Pharma Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
